Jefferies lifts target on Incyte


Jefferies has some "positive commentary from four investigators involved" in Incyte's (INCY +3.3%) Phase 2 IDO inhibitor/ ipilimumab study.

Analyst Thomas Wei thinks the combo "could show a response rate at least in the 20-30% range, materially higher than IPI alone."

Wei is "unconcerned" with reports of elevated liver enzymes.

Price target hiked to $75 from $44.

From other sites
Comments (1)
  • Polyman777
    , contributor
    Comments (6) | Send Message
     
    That is indeed good news, but I am not surpised as I have been following INCY since Mid 90's and added to my shareholding in the last 5 years inspite of the volataility.
    10 Jan 2014, 11:47 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs